Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS)
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Life sciences
More from NICE
Home
NICE guidance
In development
In development: Guidance, quality standards and advice
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic prioritisation
Filter (1 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (8)
Type
Type
Guidance (342)
Guidance programme
(
1 selected
)
Guidance programme
Clinical guidelines (27)
Diagnostics guidance (8)
Health technology evaluations (18)
HealthTech guidance (2)
Highly specialised technologies guidance (6)
Interventional procedures guidance (17)
Medical technologies guidance (10)
NICE guidelines (32)
Public health guidelines (1)
Technology appraisal guidance (342)
Apply filters
Showing 251 to 275 of 342
Sort by
Title
Date
Apply sorting
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]
Technology appraisal guidance
TBC
Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]
Technology appraisal guidance
TBC
Plozasiran for treating familial chylomicronaemia syndrome [ID6593]
Technology appraisal guidance
TBC
Polihexanide eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]
Technology appraisal guidance
18 March 2026
Radium-223 dichloride with enzalutamide for treating asymptomatic or mildly symptomatic hormone-relapsed metastatic prostate cancer with bone metastases [ID6512]
Technology appraisal guidance
7 April 2027
Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over [TSID10642][ID6319]
Technology appraisal guidance
TBC
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]
Technology appraisal guidance
15 November 2017
Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines ID6356
Technology appraisal guidance
TBC
Renal cell carcinoma Pathways Pilot [ID6186]
Technology appraisal guidance
TBC
Repotrectinib for treating NTRK fusion-positive advanced solid tumours in people 12 years and over [TSID12147]
Technology appraisal guidance
TBC
Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer [ID6277]
Technology appraisal guidance
TBC
Retifanlimab with chemotherapy for untreated PD-L1-positive metastatic non-small-cell lung cancer TSID 12007
Technology appraisal guidance
TBC
Retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy ID6482 [ID6482]
Technology appraisal guidance
TBC
Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women (ID1307)
Technology appraisal guidance
TBC
Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over [ID6395]
Technology appraisal guidance
TBC
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]
Technology appraisal guidance
TBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]
Technology appraisal guidance
TBC
Rocatinlimab for treating moderate to severe atopic dermatitis in people 12 years and over [ID6565]
Technology appraisal guidance
TBC
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596]
Technology appraisal guidance
TBC
Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]
Technology appraisal guidance
TBC
Ruxolitinib for Prurigo Nodularis [ID6571]
Technology appraisal guidance
TBC
Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]
Technology appraisal guidance
TBC
Sacituzumab govitecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [ID6375]
Technology appraisal guidance
TBC
Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer with papillary tumours or carcinoma in situ untreated with BCG ID6454
Technology appraisal guidance
TBC
Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over [ID6284]
Technology appraisal guidance
17 December 2025
Previous page
1
…
9
10
Current page
11
12
13
14
Page
11
of
14
Next page
Results per page
10
25
50
All
Back to top